2016
Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies
Samad Z, Velazquez EJ. Functional Mitral Regurgitation: Appraising the Evidence Behind Recommended Treatment Strategies. Current Cardiology Reports 2016, 18: 128. PMID: 27796864, DOI: 10.1007/s11886-016-0808-8.Peer-Reviewed Original Research
2015
Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial
Mentz RJ, Velazquez EJ, Metra M, McKendry C, Chiswell K, Fiuzat M, Givertz MM, Voors AA, Teerlink JR, O'Connor CM. Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. Future Cardiology 2015, 11: 585-595. PMID: 26403536, PMCID: PMC5558519, DOI: 10.2217/fca.15.56.Peer-Reviewed Original ResearchConceptsPROTECT trialComparative effectivenessHigher blood urea nitrogenEffects of torsemideProspective randomized trialsHeart failure patientsBlood urea nitrogenGreater disease severityDays postdischargeFailure patientsHeart failureLoop diureticsRandomized trialsRenal hospitalizationUrea nitrogenDisease severityPatientsFurosemideInverse probabilityTorsemideTrialsDeathOutcomesHospitalizationDiuretics
2014
Predictors and Progression of Aortic Stenosis in Patients With Preserved Left Ventricular Ejection Fraction
Ersboll M, Schulte PJ, Al Enezi F, Shaw L, Køber L, Kisslo J, Siddiqui I, Piccini J, Glower D, Harrison JK, Bashore T, Risum N, Jollis JG, Velazquez EJ, Samad Z. Predictors and Progression of Aortic Stenosis in Patients With Preserved Left Ventricular Ejection Fraction. The American Journal Of Cardiology 2014, 115: 86-92. PMID: 25456876, DOI: 10.1016/j.amjcard.2014.09.049.Peer-Reviewed Original ResearchConceptsModerate aortic stenosisAortic stenosisMild aortic stenosisVentricular ejection fractionMean gradientHemodynamic progressionEjection fractionClinical variablesLeft ventricular ejection fractionSevere aortic stenosisBaseline clinical variablesSubset of patientsRate of progressionEchocardiographic surveillanceRenal dysfunctionUnselected cohortAccelerated progressionLongitudinal linear regression modelsCurrent guidelinesDisease progressionRetrospective analysisPatientsSignificant interactionProgressionBaseline
2013
Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients
Givertz MM, Mann DL, Lee KL, Ibarra JC, Velazquez EJ, Hernandez AF, Mascette AM, Braunwald E. Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. Circulation Heart Failure 2013, 6: 862-868. PMID: 23861505, PMCID: PMC3902033, DOI: 10.1161/circheartfailure.113.000394.Peer-Reviewed Original ResearchEffect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial
Jiang W, Velazquez EJ, Kuchibhatla M, Samad Z, Boyle SH, Kuhn C, Becker RC, Ortel TL, Williams RB, Rogers JG, O’Connor C. Effect of Escitalopram on Mental Stress–Induced Myocardial Ischemia: Results of the REMIT Trial. JAMA 2013, 309: 2139-2149. PMID: 23695483, PMCID: PMC4378823, DOI: 10.1001/jama.2013.5566.Peer-Reviewed Original ResearchConceptsMental stress-induced myocardial ischemiaStable coronary heart diseaseExercise-induced ischemiaCoronary heart diseaseMyocardial ischemiaHeart diseaseVentricular ejection fraction reductionStress-induced myocardial ischemiaMental stressRegional wall motion abnormalitiesEjection fraction reductionPlacebo-controlled trialST-segment depressionEffect of escitalopramTertiary medical centerWall motion abnormalitiesWeeks of escitalopramSignificant differencesEnd-point assessmentStressor taskEscitalopram groupCardiac eventsEscitalopram treatmentMore patientsTreat analysisInfluence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease
Doenst T, Cleland JG, Rouleau JL, She L, Wos S, Ohman EM, Krzeminska-Pakula M, Airan B, Jones RH, Siepe M, Sopko G, Velazquez EJ, Racine N, Gullestad L, Filgueira JL, Lee KL. Influence of Crossover on Mortality in a Randomized Study of Revascularization in Patients With Systolic Heart Failure and Coronary Artery Disease. Circulation Heart Failure 2013, 6: 443-450. PMID: 23515275, PMCID: PMC3721746, DOI: 10.1161/circheartfailure.112.000130.Peer-Reviewed Original ResearchMeSH KeywordsAgedComorbidityCoronary Artery BypassCoronary Artery DiseaseCross-Over StudiesDisease ProgressionFemaleHeart Failure, SystolicHumansMaleMiddle AgedConceptsHeart failureCoronary artery bypass graft surgeryIschemic Heart Failure (STICH) trialPatient/family decisionArtery bypass graft surgeryImpact of CABGBypass graft surgeryHeart Failure TrialMultivariable Cox modelSystolic heart failureCoronary artery diseaseIschemic heart diseaseAcute decompensationGraft surgeryProgressive symptomsArtery diseaseMedical therapySurgical treatmentFailure TrialPatient populationHeart diseaseCABGCommon reasonCox modelPatients
2012
Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction
Meris A, Amigoni M, Verma A, Thune JJ, Køber L, Velazquez E, McMurray JJ, Pfeffer MA, Califf R, Levine RA, Solomon SD, Investigators V. Mechanisms and Predictors of Mitral Regurgitation after High-Risk Myocardial Infarction. Journal Of The American Society Of Echocardiography 2012, 25: 535-542. PMID: 22305962, PMCID: PMC3501447, DOI: 10.1016/j.echo.2012.01.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAngiotensin-Converting Enzyme InhibitorsCaptoprilDisease ProgressionEchocardiography, Doppler, ColorElectrocardiographyFemaleFollow-Up StudiesHumansMaleMiddle AgedMitral Valve InsufficiencyMonitoring, PhysiologicMultivariate AnalysisMyocardial InfarctionPredictive Value of TestsProspective StudiesReference ValuesReproducibility of ResultsRisk AssessmentROC CurveSeverity of Illness IndexSex FactorsStatistics, NonparametricStroke VolumeTetrazolesTime FactorsValineValsartanVentricular Dysfunction, LeftVentricular RemodelingConceptsHigh-risk myocardial infarctionBaseline mitral regurgitationMitral regurgitationMyocardial infarctionAtrial sizeIndependent predictorsCoaptation depthProgression of MRMitral valve deformationStructural valve diseaseSevere mitral regurgitationFunctional mitral regurgitationIschemic mitral regurgitationGood-quality echocardiogramsMitral annular areaMitral tentingMR degreeLV dysfunctionTenting areaBaseline characteristicsDiastolic functionHeart failureValve diseaseLV remodelingVentricular remodeling
2010
The STICH trial: evidence‐based conclusions
Rouleau JL, Michler RE, Velazquez EJ, Oh JK, O'Connor CM, Desvigne‐Nickens P, Sopko G, Lee KL, Jones RH. The STICH trial: evidence‐based conclusions. European Journal Of Heart Failure 2010, 12: 1028-1030. PMID: 20861132, DOI: 10.1093/eurjhf/hfq140.Peer-Reviewed Original ResearchMechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both
Shin SH, Hung CL, Uno H, Hassanein AH, Verma A, Bourgoun M, Køber L, Ghali JK, Velazquez EJ, Califf RM, Pfeffer MA, Solomon SD. Mechanical Dyssynchrony After Myocardial Infarction in Patients With Left Ventricular Dysfunction, Heart Failure, or Both. Circulation 2010, 121: 1096-1103. PMID: 20176989, DOI: 10.1161/circulationaha.109.863795.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalog-Digital ConversionAngiotensin II Type 1 Receptor BlockersDeathDisease ProgressionFemaleFollow-Up StudiesHeart FailureHumansMaleMiddle AgedMotionMyocardial ContractionMyocardial InfarctionPrognosisProportional Hazards ModelsStress, MechanicalTetrazolesUltrasonographyValineValsartanVentricular Dysfunction, LeftVideo RecordingConceptsSD of timeLeft ventricular dysfunctionHeart failureMyocardial infarctionMechanical dyssynchronyVentricular dysfunctionIndependent predictorsPost-myocardial infarction prognosisPeak velocityAdverse cardiovascular outcomesMultivariate Cox modelRisk of deathLeft ventricular segmentsMeasures of dyssynchronyVelocity vector imagingCardiovascular outcomesEchocardiographic variablesVentricular synchronyVentricular dyssynchronyClinical outcomesEchocardiography studyRisk factorsContractile patternsVentricular segmentsCox modelRenal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, investigators F. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. The Lancet 2010, 375: 1173-1181. PMID: 20170948, DOI: 10.1016/s0140-6736(09)62100-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlbuminuriaAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCardiovascular DiseasesCreatinineDisease ProgressionDiureticsDouble-Blind MethodDrug CombinationsFemaleGlomerular Filtration RateHumansHydrochlorothiazideHypertensionKidney Failure, ChronicMaleMiddle AgedRisk FactorsConceptsChronic kidney diseaseKidney diseaseAmlodipine groupHydrochlorothiazide groupCardiovascular eventsCombination therapyHigh riskChronic kidney disease progressionEnd-stage renal diseaseFixed-dose combination therapyAvoiding Cardiovascular EventsBlood pressure goalsInitial antihypertensive therapyInitial antihypertensive treatmentPrespecified secondary analysisProgression of nephropathySystolic Hypertension (ACCOMPLISH) trialFrequent adverse eventsKidney disease progressionSerum creatinine concentrationTelephone-based interactive voice response systemAntihypertensive therapyAntihypertensive treatmentRenal outcomesCardiovascular morbidity
2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function
Amigoni M, Meris A, Thune JJ, Mangalat D, Skali H, Bourgoun M, Warnica JW, Barvik S, Arnold JM, Velazquez EJ, Van de Werf F, Ghali J, McMurray JJ, Køber L, Pfeffer MA, Solomon SD. Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and function. European Heart Journal 2007, 28: 326-333. PMID: 17251259, DOI: 10.1093/eurheartj/ehl464.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiac VolumeDisease ProgressionEchocardiography, Doppler, ColorElectrocardiographyFemaleHeart FailureHumansMaleMiddle AgedMitral Valve InsufficiencyMyocardial InfarctionObserver VariationPrognosisProspective StudiesRandomized Controlled Trials as TopicRisk FactorsVentricular Dysfunction, LeftVentricular RemodelingConceptsProgression of MRBaseline mitral regurgitationHeart failureMitral regurgitationAcute myocardial infarctionMyocardial infarctionVentricular sizeMR severityHigh-risk myocardial infarctionModerate-severe mitral regurgitationBaseline MR severityWorse LV functionEnd-systolic volumeLarger LV volumesRegurgitant jet areaAtrial area ratioCV mortalityHF hospitalizationCardiovascular outcomesSystolic dysfunctionVentricular dysfunctionEjection fractionIndependent predictorsClinical outcomesLV function